Effect of buffer pH, buffer concentration and skin with or without enzyme inhibitors on the stability of [Arg8]-vasopressin

被引:6
作者
Bi, MD [1 ]
Singh, J [1 ]
机构
[1] N Dakota State Univ, Coll Pharm, Dept Pharmaceut Sci, Fargo, ND 58105 USA
关键词
stability; vasopressin; pH; buffer concentration; skin; enzyme inhibitors;
D O I
10.1016/S0378-5173(99)00459-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The stability of [Arg(8)]-vasopressin (AVP) as a function of buffer pH, buffer concentration, salt concentration, temperature, and skin with and without enzyme inhibitors was investigated. AVP was analyzed by reverse-phase high-performance liquid chromatography. The results indicated that the buffer's pH affected the degradation rate of AVP. Buffer ions (H2PO4 and HPO42-) and salt concentrations had no effect on the degradation of AVP. Maximum stability was achieved at pH 3.35 among pH values tested. The activation energy for the overall reaction was 21.5 kcal mol(-1) at pH 3.35. From the Arrhenius equation, the shelf-life of AVP at 25 degrees C and pH 3.35 was calculated to be 1.38 years. The degradation rate of AVP in the skin (area: 9 cm(2), thickness: 0.5 mm) was 0.22 h(-1). Bestatin (an aminopeptidase inhibitor) had the best stabilizing effect on the degradation of AVP by skin among the three enzyme inhibitors (i.e. aprotinin, bestatin, and leupeptin) studied. The degradation rate of AVP in the skin was reduced to 0.059 h(-1) in the presence of bestatin in comparison with no inhibitor (0.22 h(-1)). (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 21 条
[1]   LUTEINIZING-HORMONE-RELEASING HORMONE PEPTIDASE ACTIVITIES IN DISCRETE HYPOTHALAMIC REGIONS AND ANTERIOR-PITUITARY OF THE RAT - APPARENT REGULATION DURING THE PREPUBERTAL PERIOD AND 1ST ESTROUS-CYCLE AT PUBERTY [J].
ADVIS, JP ;
KRAUSE, JE ;
MCKELVY, JF .
ENDOCRINOLOGY, 1982, 110 (04) :1238-1245
[2]   TRANSDERMAL IONTOPHORETIC DELIVERY AND DEGRADATION OF VASOPRESSIN ACROSS HUMAN CADAVER SKIN [J].
BANGA, AK ;
KATAKAM, M ;
MITRA, R .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 116 (02) :211-216
[3]   Degradation of luteinizing hormone releasing hormone in buccal, liver, nasal and skin tissues [J].
Bi, M ;
Singh, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 175 (02) :269-273
[4]   HPLC method for quantification of arginine containing vasopressin [J].
Bi, MD ;
Singh, J .
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 1999, 22 (04) :551-560
[5]   CHEMICAL-STABILITY OF INSULIN .1. HYDROLYTIC DEGRADATION DURING STORAGE OF PHARMACEUTICAL PREPARATIONS [J].
BRANGE, J ;
LANGKJAER, L ;
HAVELUND, S ;
VOLUND, A .
PHARMACEUTICAL RESEARCH, 1992, 9 (06) :715-726
[6]   OPIATE INHIBITION OF PEPTIDE RELEASE FROM THE NEUROHUMORAL TERMINALS OF HYPOTHALAMIC NEURONS [J].
CLARKE, G ;
WOOD, P ;
MERRICK, L ;
LINCOLN, DW .
NATURE, 1979, 282 (5740) :746-748
[7]   INTERRELATIONSHIP BETWEEN RELEASE OF RENIN AND VASOPRESSIN AS DEFINED BY ORTHOSTASIS AND PROPRANOLOL [J].
DAVIES, R ;
FORSLING, ML ;
SLATER, JDH .
JOURNAL OF CLINICAL INVESTIGATION, 1977, 60 (06) :1438-1441
[8]   Kinetics of diketopiperazine formation using model peptides [J].
Goolcharran, C ;
Borchardt, RT .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (03) :283-288
[9]   STABILITY OF THE SYNTHETIC PENTAPEPTIDE THYMOPENTIN IN AQUEOUS-SOLUTION - EFFECT OF PH AND BUFFER ON DEGRADATION [J].
HELM, VJ ;
MULLER, BW .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1991, 70 (1-2) :29-34
[10]   Degradation kinetics of gonadorelin in aqueous solution [J].
Hoitink, MA ;
Beijnen, JH ;
Bult, A ;
vanderHouwen, OAGJ ;
Nijholt, J ;
Underberg, WJM .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (10) :1053-1059